{
    "clinical_study": {
        "@rank": "141110", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl\n      sustained release) 50/1000mg(25/500mg x 2tablets)"
        }, 
        "brief_title": "Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 2"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 to 45, healthy male subjects(at screening)\n\n          -  BMI between 19.0 - 27.0\n\n          -  FPG 70-125mg/dL glucose level(at screening)\n\n          -  Subject who totally understand the progress of this clinical trials, make decision by\n             his free will, and signed a consent form to follow the progress.\n\n        Exclusion Criteria:\n\n          -  Subject who has past or present history of any diseases following below.(liver\n             including hepatitis virus carrier, kidney,\n             Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)\n\n          -  Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis)\n             surgery.(appendectomy, hernioplasty are not included)\n\n          -  Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)\n\n          -  Subject who already participated in other trials in 90 days\n\n          -  Subject who had whole blood donation in 60 days, or component blood donation in 30\n             days or transfusion in 30 days currently.\n\n          -  Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747083", 
            "org_study_id": "LG-DMCL003"
        }, 
        "intervention": {
            "arm_group_label": [
                "A", 
                "B"
            ], 
            "intervention_name": "FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Single Dose, Crossover Study to Investigate Food-effect Bioavailability of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)Under Fed and Fasting Conditions in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South korea: Korea Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate AUClast of gemigliptin and metformin", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "up to 48 h post-dose"
            }, 
            {
                "description": "TO evaluate Cmax of gemigliptin and metformin", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 48 h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747083"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate AUCinf of gemigliptin,metformin and LC15-0636(active metabolite of gemigliptin)", 
                "measure": "AUCinf", 
                "safety_issue": "No", 
                "time_frame": "up to 48 h post-dose"
            }, 
            {
                "description": "To evaluate Tmax of gemigliptin, metformin and LC15-0636(active metabolite of gemigliptim)", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "up to 48h post-dose"
            }, 
            {
                "description": "To evaluate t1/2 of gemigliptin, metformin and LC15-0636(active metabolite of gemigliptim)", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "up to 48 h post-dose"
            }, 
            {
                "description": "To evaluate Cmax of LC15-0636(active metabolite of gemigliptim)", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 48h post-dose"
            }, 
            {
                "description": "To evaluate AUClast of LC15-0636(active metabolite of gemigliptim)", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "up to 48h post-dose"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}